Search Within
Applied Filters:
Showing 1-30 of 38 results for "


" within Papers
Sort by Relevance
Erin L Karschner et al.
Journal of analytical toxicology, 33(8), 469-477 (2009-10-31)
Delta(9)-Tetrahydrocannabinol (THC) is commonly found in toxicological specimens from driving under the influence and accident investigations. Plasma cannabinoid concentrations were determined in 18 long-term heavy cannabis smokers residing on an in-patient research unit for seven days of monitored abstinence. THC
Alex Straiker et al.
British journal of pharmacology, 165(8), 2660-2671 (2011-10-22)
Cannabinoids such as Δ(9) - tetrahydrocannabinol, the major psychoactive component of marijuana and hashish, primarily act via cannabinoid CB(1) and CB(2) receptors to produce characteristic behavioural effects in humans. Due to the tractability of rodent models for electrophysiological and behavioural
Ross H Lowe et al.
Drug and alcohol dependence, 105(1-2), 24-32 (2009-07-28)
Generally, urinary 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCCOOH) after alkaline hydrolysis is monitored to detect cannabis exposure, although last use may have been weeks prior in chronic cannabis users. Delta9-Tetrahydrocannabinol (THC) and 11-hydroxy-THC (11-OH-THC) concentrations in urine following Escherichia coli beta-glucuronidase hydrolysis were proposed
Markus Joerger et al.
Drug metabolism letters, 6(2), 102-108 (2012-05-19)
Cannabinoids exert neuroprotective and symptomatic effects in amyotrophic lateral sclerosis (ALS). We assessed the pharmacokinetics (PK) and tolerability of delta-9-tetrahydrocannabinol (THC) in ALS patients. Nine patients received THC single oral doses of 5mg and 10mg, separated by a wash-out period
Eugene W Schwilke et al.
Clinical chemistry, 55(12), 2180-2189 (2009-10-17)
Delta(9)-tetrahydrocannabinol (THC) is the primary psychoactive constituent of cannabis and an active cannabinoid pharmacotherapy component. No plasma pharmacokinetic data after repeated oral THC administration are available. Six adult male daily cannabis smokers resided on a closed clinical research unit. Oral
Stefan W Toennes et al.
Archiv fur Kriminologie, 225(3-4), 90-98 (2010-05-29)
When defendants are confronted with evidence of cannabinoids in their blood suggesting consumption of cannabis they sometimes argue that this could only be due to a passive exposure. The small number of controlled studies available showed that tetrahydrocannabinol (THC), the
Marie Fabritius et al.
Forensic science international, 223(1-3), 114-118 (2012-09-18)
The metabolism of Δ(9)-tetrahydrocannabinol (THC) is relatively complex, and over 80 metabolites have been identified. However, much less is known about the formation and fate of cannabinoid conjugates. Bile excretion is known to be an important route for the elimination
Gisela Skopp et al.
Journal of analytical toxicology, 32(2), 160-164 (2008-03-13)
A blood concentration of tetrahydrocannabinol (THC) in the low nanograms-per-milliliter range is often claimed to result from drug use more than 24-48 h previously. The present investigation determined concentrations of cannabinoids in blood collected at least 24 h from smoking
J Röhrich et al.
Journal of analytical toxicology, 34(4), 196-203 (2010-05-15)
Cannabinoid concentrations in blood and urine after passive exposure to cannabis smoke under real-life conditions were investigated in this study. Eight healthy volunteers were exposed to cannabis smoke for 3 h in a well-attended coffee shop in Maastricht, Netherlands. An
Matthijs G Bossong et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 34(3), 759-766 (2008-08-30)
The influence of cannabis on mental health receives growing scientific and political attention. An increasing demand for treatment of cannabis dependence has refueled the discussion about the addictive potential of cannabis. A key feature of all addictive drugs is the
Carsten Rygaard Hjorthøj et al.
Addiction (Abingdon, England), 107(6), 1123-1131 (2011-12-14)
To assess correlations and agreement between timeline follow-back (TLFB)-assisted self-report and blood samples for cannabis use. Secondary analysis of a randomized trial. Copenhagen, Denmark. One hundred and three patients from the CapOpus trial with cannabis use disorder and psychosis, providing
Maria Del Mar Ramirez Fernandez et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 875(2), 465-470 (2008-10-17)
Cannabis is considered to be the most widely abused illicit drug in Europe. Consequently, sensitive and specific analytical methods are needed for forensic purposes and for cannabinoid pharmacokinetic and pharmacodynamic studies. A simple, rapid and highly sensitive and specific method
Cynthia Coulter et al.
Journal of analytical toxicology, 32(8), 653-658 (2008-11-15)
An analytical procedure for the determination of Delta9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA), and 11-hydroxy-Delta9-tetrahydrocannabinol (11-OH-THC) in whole blood has been developed and validated using liquid chromatography with tandem mass spectral detection (MS). Cannabinoids present in the blood samples were quantified using
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications
David M Schwope et al.
Journal of analytical toxicology, 36(6), 405-412 (2012-05-17)
Δ⁹-Tetrahydrocannabinol (THC) is the illicit drug most frequently observed in accident and driving under the influence of drugs investigations. Whole blood is often the only available specimen collected during such investigations, yet few studies have examined relationships between cannabis effects
David A Gorelick et al.
Journal of clinical psychopharmacology, 31(5), 603-612 (2011-08-27)
Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis
Erin L Karschner et al.
Analytical and bioanalytical chemistry, 397(2), 603-611 (2010-03-23)
A sensitive analytical method for simultaneous quantification of sub-nanogram concentrations of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) in plasma is presented for monitoring cannabinoid pharmacotherapy and illicit cannabis use. Analytes were extracted from 1 mL plasma by
Nathalie A Desrosiers et al.
Clinical chemistry, 60(4), 631-643 (2014-02-25)
Δ(9)-Tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) have been reported in blood from frequent cannabis smokers for an extended time during abstinence. We compared THC, 11-OH-THC, THCCOOH, cannabidiol, cannabinol, THC-glucuronide, and 11-nor-9-carboxy-THC-glucuronide (THCCOO-glucuronide) blood and plasma disposition in frequent and
Gisela Skopp et al.
Archiv fur Kriminologie, 229(5-6), 154-162 (2012-07-28)
The exculpatory statement that a positive THC finding in the blood is due to the consumption of hemp products or passive exposure to cannabis smoke has been disproved by the monitoring of hemp products and recent passive inhalation studies conducted
Steffen Heide et al.
Journal of forensic and legal medicine, 19(7), 431-433 (2012-08-28)
A 26-year-old man, after a drinking binge, drove into a tram building site and collided with a track-grinding machine which left a fist-size hole in his windscreen. He then hit a construction worker who was catapulted onto the car roof.
Nathalie A Desrosiers et al.
Clinical chemistry, 58(10), 1418-1425 (2012-08-23)
Oral fluid (OF) testing offers noninvasive sample collection for on-site drug testing; however, to date, test performance for Δ(9)-tetrahydrocannabinol (THC) detection has had unacceptable diagnostic sensitivity. On-site tests must accurately identify cannabis exposure because this drug accounts for the highest
Claudine C Hunault et al.
Psychopharmacology, 201(2), 171-181 (2008-08-13)
Delta9-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). The pharmacokinetics of THC after smoking cannabis cigarettes
David M Schwope et al.
Clinical chemistry, 57(10), 1406-1414 (2011-08-13)
Δ⁹-Tetrahydrocannabinol (THC) is the most frequently observed illicit drug in investigations of accidents and driving under the influence of drugs. THC-glucuronide has been suggested as a marker of recent cannabis use, but there are no blood data following controlled THC
Ross H Lowe et al.
Journal of chromatography. A, 1163(1-2), 318-327 (2007-07-21)
A two-dimensional (2D) gas chromatography/electron impact-mass spectrometry (GC/EI-MS) method for simultaneous quantification of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma was developed and validated. The method employs 2D capillary GC and cryofocusing for enhanced resolution and
Tsadik T Abraham et al.
Journal of analytical toxicology, 31(8), 477-485 (2007-11-09)
A sensitive and specific method for extraction and quantification of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in human urine was developed and fully validated. To ensure complete hydrolysis of conjugates and capture of total analyte content, urine samples were
Garry Milman et al.
Clinical chemistry, 57(11), 1597-1606 (2011-08-31)
Oral fluid (OF) testing is increasingly important for drug treatment, workplace, and drugged-driving programs. There is interest in predicting plasma or whole-blood concentrations from OF concentrations; however, the relationship between these matrices is incompletely characterized because of few controlled drug-administration
D Corbett et al.
The Journal of antimicrobial chemotherapy, 70(6), 1751-1756 (2015-02-06)
SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical isolates (which included ribotype 027 isolates and isolates with reduced metronidazole
Anna Orlova et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(6), 961-968 (2013-03-27)
Because of their better penetration, smaller targeting proteins may be superior to antibodies for radioimmunotherapy of solid tumors. Therefore, Affibody molecules (6.5 kDa) have a potential for being suitable as targeted moiety for radiolabeled therapeutic proteins. Previous studies have demonstrated
C H Chilton et al.
Journal of medical microbiology, 63(Pt 4), 489-503 (2014-01-22)
The soluble proteome of three Clostridium difficile strains of varying pathogenic potential, designated B-1, Tra 5/5 and 027 SM, were compared using differential in-gel electrophoresis in which the proteins of each strain were labelled with CyDyes. This enabled visual inspection
April Roberts et al.
Infection and immunity, 80(2), 875-882 (2011-12-07)
Treatment of Clostridium difficile is a major problem as a hospital-associated infection which can cause severe, recurrent diarrhea. The currently available antibiotics are not effective in all cases and alternative treatments are required. In the present study, an ovine antibody-based
Page 1 of 2
Page 1 of 2